BioVie's liver disease drug company Option Therapeutics (OPTN.US) shrinks IPO size and reduces fundraising amount by 20% to $20 million.

On Monday, Option Therapeutics (OPTN.US), a clinical-stage liver disease biotechnology company spun off from BioVie, has reduced the size of its upcoming IPO. The company, headquartered in Carson City, Nevada, now plans to raise $20 million by issuing 1.8 million shares priced between $10 and $12. Previously, the company had applied to issue 2.3 million shares in the same price range. Based on the midpoint of the price range, Option Therapeutics' fundraising amount will be reduced by 20% compared to previous expectations. The company focuses on developing candidate drugs for severe and life-threatening liver diseases. Its lead product, BIV201, is currently being evaluated for the treatment of complications associated with advanced liver cirrhosis, and patent applications have been submitted in the US, China, Japan, Chile, and India. Option Therapeutics has not generated any revenue at present. Option Therapeutics was founded in 2025 and plans to list on the NYSE American stock exchange with the ticker symbol OPTN. ThinkEquity serves as the exclusive book-running manager for the offering.